A sensitive and accurate tuberculosis (TB) serodiagnostic test would aid in the control of TB, but results of current tests are relatively unreliable for persons infected with human immunodeficiency virus (HIV). We evaluated a new prototype immunochromatographic strip test and 5 commercially available serodiagnostic TB tests in a prospective study comprised of 465 consecutively enrolled patients with suspected TB from 2 hospitals in Botswana. Consenting adults underwent HIV testing, у2 sputum smears and cultures, and mycobacterial blood culture. Patients were defined as having TB on the basis of any positive smear or culture. Between January and September 2002, 465 of 498 consecutive patients consented to enrollment. A total of 384 patients (83%) were infected with HIV, and 175 (38%) had TB; the mycobacterial blood culture was the sole source of diagnosis for 26 patients (15%) with TB. Among the tests evaluated, the sensitivity was 0%-63%, the specificity was 39%-99%, the positive predictive value was 0%-39%, and the negative predictive value was 63%-65%. We conclude that the serodiagnostic tests evaluated in this study lacked sufficient sensitivity as sole tests for TB in this population.
A sensitive and accurate tuberculosis (TB) serodiagnostic test would aid in the control of TB, but results of current tests are relatively unreliable for persons infected with human immunodeficiency virus (HIV). We evaluated a new prototype immunochromatographic strip test and 5 commercially available serodiagnostic TB tests in a prospective study comprised of 465 consecutively enrolled patients with suspected TB from 2 hospitals in Botswana. Consenting adults underwent HIV testing, у2 sputum smears and cultures, and mycobacterial blood culture. Patients were defined as having TB on the basis of any positive smear or culture. Between January and September 2002, 465 of 498 consecutive patients consented to enrollment. A total of 384 patients (83%) were infected with HIV, and 175 (38%) had TB; the mycobacterial blood culture was the sole source of diagnosis for 26 patients (15%) with TB. Among the tests evaluated, the sensitivity was 0%-63%, the specificity was 39%-99%, the positive predictive value was 0%-39%, and the negative predictive value was 63%-65%. We conclude that the serodiagnostic tests evaluated in this study lacked sufficient sensitivity as sole tests for TB in this population.
The current pandemic of HIV infection has contributed substantially to the recent increase in the worldwide incidence of tuberculosis (TB) [1] . TB is already the leading cause of death among people with AIDS, accounting for almost one-third of deaths among HIVinfected patients worldwide and ∼40% of deaths among such patients in Africa alone [2] . In Botswana in 2001, the TB rate was 620 per 100,000 population [3] , and the HIV prevalence among antenatal women was 35% [4] . Among hospitalized patients with suspected TB in 2001, 84% were infected with HIV [5] .
Since 1996, the World Health Organization has promoted the strategy of "directly observed therapy, short course" for TB control, one aspect of which is case detection using sputum smear microscopy for patients with suspected TB in general health services [6] . The emphasis on TB diagnosis by sputum smear microscopy has limitations, primarily because the sensitivity-when direct, unconcentrated methods are used-is 40%-60% for a combination of 3 examinations [7, 8] and is lower for those with HIV coinfection [9] . Additionally, persons with HIV infection are more likely to have extrapulmonary manifestations of TB disease.
Serodiagnostic technology offers the potential for a rapid, inexpensive field-test for TB. The US Food and Drug Administration (FDA) has proposed 6 performance criteria for the ideal TB test (M. Goldberg, personal communication). A serological test should be accurate, with adequate performance to monitor response to therapy; able to discriminate between latent and active Mycobacterium tuberculosis infection, previous bacille Calmette-Guérin vaccination, or exposure to other potentially cross-reacting nontuberculous mycobacteria; rapid (duration, !25 min); capable of testing few or many patients; simple and safe for use by technicians without extensive training; stable at ambient temperature for up to 2 years; and affordable.
An immunochromatographic strip (ICS) test was developed by the Program for Appropriate Technology in Health (PATH; Seattle) with funds from the US Agency for International Development. The PATH prototype ICS test was used to retrospectively screen a panel of serum samples obtained from 284 HIV-negative adult patients in 4 African countries and Brazil, India, and Indonesia. Compared with culture, the mean sensitivity of the ICS test was 72% (range, 62%-100%). The specificity was 79% for ICS analysis of only 89 specimens from culture-negative subjects. ICS testing of specimens obtained from 92 HIV-infected subjects had a sensitivity of 41%; the specificity has not been quantified for HIV-infected subjects.
The chief goal of this study was to prospectively evaluate, under field conditions, the programmatic use and accuracy of ICS testing among inpatients with suspected TB. This study was also designed to assess the sensitivity and specificity of 5 other commercially available products or newly developed prototypes for TB serodiagnostic analysis.
PATIENTS, MATERIALS, AND METHODS

Patients.
Patients aged у18 years who had suspected TB and were hospitalized at either of the country's 2 referral hospitals were eligible for enrollment. Patients were defined as having suspected TB if they had a history of cough lasting у2 weeks and were identified by their supervising physician as needing an evaluation for TB. They were prospectively identified by research staff who attended the hospital physicians' morning report.
Research staff explained the purpose and the conduct of the study and requested written informed consent in the patient's native language or in English. Approval for human subjects research was obtained from an institutional review board of the US Centers for Disease Control and Prevention, the PATH Human Subjects Protection Committee, the Health Research and Development Committee (Botswana) , and the ethics review boards of the 2 participating hospitals.
Once enrolled, subjects underwent evaluations considered to be routine for suspected TB in Botswana: blood samples were obtained by phlebotomy for HIV testing and measurement of CD4 + T lymphocyte count. Additionally, posteroanterior chest radiographs were obtained and read by the hospital staff radiologist, who was unaware of results of the serodiagnostic tests. Each patient was instructed to provide 2 sputum specimens produced at random times and 1 produced during the early morning for acid-fast bacillus (AFB) smearing and culture within 72 h of enrollment. A patient who could not produce sputum specimens underwent sputum induction, which was performed using 3% normal saline. In addition, blood was cultured for bacteria and mycobacteria. A tuberculin skin test (TST) using 2 tuberculin units of RT23 was performed, and induration was measured 48-72 h later. Other tests were performed at the discretion of the attending physician.
HIV testing. Serum HIV testing was performed according to the guidelines and procedures approved by the Botswana Ministry of Health at the time of the study. Serum samples were evaluated using 2 ELISA tests run in parallel (Murex HIV 1.2.0, Murex Biotech; and Ortho HIV1/HIV2 Capture ELISA System, Ortho Clinical Laboratories), each of which can detect HIV-1 and HIV-2. HIV infection was defined as 2 positive ELISA results. Non-HIV infection was defined as 2 negative ELISA results. Discordant results were resolved with Western blot testing.
Mycobacterial testing. AFB smears were analyzed using Ziehl-Neelsen staining. Sputum was cultured for mycobacteria on Lowenstein-Jensen slants using MGIT (Becton Dickinson), in accordance with the manufacturer's instructions. Blood was cultured for mycobacteria using MycoF Lytic (Becton Dickinson), in accordance with the manufacturer's instructions.
Serological testing. A total of 4 rapid tests (PATH ICS test, American Bionostica, Osborne Scientific, and MycoDot [Dynogen]) and 2 ELISAs (Omega Diagnostics and Anda Biologicals) were evaluated in this study. All laboratory personnel were trained in the use of rapid serological and ELISA-based tests before patient enrollment and testing. All non-ELISA-based testing was conducted on blood serum specimens, and PATH ICS testing was conducted on whole blood specimens on the days on which specimens were obtained. Serum specimens obtained for ELISA-based testing were frozen to Ϫ70ЊC on the day of collection and were tested when enrollment was completed. All tests were interpreted in accordance with manufacturers' or developers' instructions. The test reader was blinded to the patients' clinical status and the results of all other clinical tests. The rapid tests were read by 2 independent readers, and any discrepancy between the 2 readers was resolved by a third independent reader who was blinded to the findings of the 2 readers and the results of the clinical tests. For the ELISAs, indeterminate results were not included in performance calculations. For the Anda Biologicals ELISAs, an integrated positive result was calculated using any positive results of the IgG, IgM, and IgA ELISAs. Similarly, integrated negative and indeterminate test results were calculated using any negative or indeterminate results with the IgG, IgM, and IgA ELISAs.
Statistical analysis. Patients were defined as having TB disease on the basis of a positive AFB sputum smear or a sputum or blood culture that yielded M. tuberculosis. Statistical analysis was performed using Epi Info 6.04d for determination of the specificity and positive and negative predictive values of the serodiagnostic tests [10] .
Because a gold standard for TB diagnosis does not exist, a sensitivity analysis was also performed. Patients were grouped according to potential risk factors for TB, including HIV seropositivity, positive results of TST, abnormal chest radiograph findings, and reported history of exposure to TB or active TB disease. We then assumed that patients had active TB at the time of evaluation, regardless of whether it was detected by sputum smears or culture, blood culture, or some combination of these, and recalculated the sensitivity of the ICS test.
RESULTS
Patients.
Of 498 consecutive eligible patients with suspected TB, 465 (93%) agreed to participate and were enrolled between January and September 2002. The median age was 36 years (range, 21-89 years); 53% were men. Characteristics by TB status are shown in table 1. Univariate analysis revealed that subjects with TB disease were less likely to report headache and a previous diagnosis of TB and were more likely to be younger and have night sweats than were subjects without TB. Diagnostic evaluations. Table 2 summarizes the clinical characteristics of patients according to TB status. Overall, 384 patients (83%) were infected with HIV, 39 (8%) were HIV negative, and 42 (9%) declined testing or had missing results. Among 370 HIV-infected subjects for whom CD4 + T lymphocyte counts were available, the mean T lymphocyte count was 81 cells/mL (median, 41 cells/mL); among 37 HIV-negative subjects, the mean CD4 + T lymphocyte count was 495 cells/mL (median, 518 cells/mL). Among HIV-infected subjects, 324 (84%) had a CD4 + T lymphocyte count !200 cells/mL. A total of 382 subjects (82%) had an abnormal chest radiograph finding, of whom 369 (97%) had infiltrates, 52 (14%) had pleural effusions, 21 (5%) had cavities, 21 (5%) had a miliary pattern, and 1 (!1%) had a mass lesion. TB was diagnosed in 175 (38%) of 465 study subjects and was identified on the basis of sputum smears and/or culture only for 92 (53%), sputum examination (smear and/or culture) and blood culture for 57 (33%); and blood culture only for 26 (15%). Thus, mycobacterial blood culture yielded M. tuberculosis for 83 (18%) of 465 study subjects.
Among the 175 patients with TB, 72 (41%) had positive results of sputum smear and culture, 38 (22%) had positive smear results and negative culture results (12 had positive blood culture results-that is, results of sputum cultures were falsely negative), and 39 (22%) had negative smear results and positive culture results (8 had positive blood culture results-that is, sputum smears were negative for M. tuberculosis). The remainder of the patients with TB (26 [15%]) received diagnoses solely on the basis of positive blood culture results. Sputum induction was performed a total of 74 times for 39 subjects. Twelve patients were identified as having pulmonary TB solely on the basis of analysis of specimens obtained from sputum induction.
There were no statistically significant differences in mean TST sizes between patients with and patients without TB, regardless of whether TST readings of 0 mm were excluded from analysis (table 2) . However, when readings of 0 mm were included, mean TST sizes were lower for those with HIV infection than for those without (1.8 vs. 5.6 mm;
), but when P ! .001 such readings were excluded, mean TST sizes were not signif- ). In univariate analysis, subjects with TB disease were P p .3 significantly more likely to have HIV infection, a CD4 + Tlymphocyte count !200 cells/mL, and lower hemoglobin levels, hematocrit, and platelet counts than were subjects without TB (table 2) .
Results of serodiagnostic analysis. The sensitivity, specificity, and positive and negative predictive values of the serodiagnostic tests are shown in table 3 . When used to analyze serum specimens, the ICS test showed an overall sensitivity and specificity of 25% and 75%, respectively. Results of the ICS test were less satisfactory when used to analyze whole blood. When considered on the basis of its 3 component antigens, no single antigen outperformed the integrated result. When stratified by HIV infection status, the ICS test (serum) showed higher sensitivity for HIV-negative patients, compared with HIV-positive patients (40% vs. 26%), but the specificity was lower (65% vs. 76%). When stratified by CD4 + T lymphocyte count 1200 cells/ mL, the ICS test showed higher sensitivity for patients with higher CD4 + T lymphocyte counts, compared with those with !200 cells/mL (32% vs. 26%), but lower specificity (61% vs. 79%). When stratified by diameter of the TST reaction, the ICS test showed higher sensitivity for a TST diameter 15 mm, compared with a diameter !5 mm (38% vs. 26%), but lower specificity (71% vs. 75%). When stratified by chest radiograph findings, the ICS test showed higher sensitivity for subjects with abnormal findings, compared with those with unremarkable findings (26% vs. 7%), but lower specificity (76% vs. 88%).
Compared with the overall findings, there was no significant difference in the results of the ICS test for patients with sputum smears negative for AFB (sensitivity 25% and specificity 74%) or for patients with a negative mycobacterial blood cultures (sensitivity 29% and specificity 75%).
Results of the sensitivity analysis for the ICS are shown in table 4. We assumed that all patients had active TB, regardless of whether TB was detected by sputum smearing and/or culture and/or by blood culture. We then recalculated the sensitivity of the ICS test. Statistical analysis revealed that sensitivity does not significantly improve in scenarios with 1100 high-risk TB suspects. When analyzed in combination, the PATH ICS and Osborne Scientific tests together were 56% sensitive but only 46% specific for TB disease. For the Anda IgG, IgM, and IgA tests, 28%, 18%, and 15% of results, respectively, were indeterminate; for Omega, 34% of results were indeterminate.
DISCUSSION
In this study, TB and advanced HIV infection were relatively common among hospitalized patients with a history of cough lasting у2 weeks. We found that the mycobacterial blood culture was a useful adjunct for TB diagnosis: 15% of all TB cases were diagnosed solely on the basis of blood culture results. This finding is consistent with those of previous reports [11, 12] .
The subjects in and the setting of our study comprise the clinical scenario in which a TB serodiagnostic test is most needed: patients with suspected TB in a hospital with a high prevalence of HIV infection. The serodiagnostic tests we eval-uated had a poor ability to detect TB in this population. The literature is replete with apparently successful evaluations of various TB diagnostic tests [13] [14] [15] [16] [17] . However, unlike our study, often only patients with AFB sputum smear-positive pulmonary TB disease are included, and those with paucibacillary pulmonary (i.e., AFB sputum smear-negative) disease (which may elicit a less vigorous host antibody response [18] ) and control subjects with diseases that mimic TB (e.g., endemic mycotic or nontuberculous mycobacterial disease or sarcoidosis) are not.
Because HIV infection has become such a prominent feature of the TB epidemic in many parts of the world, evaluations of new tests should examine the effects of HIV on serodiagnostic assay results. In initial studies performed in preparation for commercial release of the MycoDot assay, sensitivity was 63% among HIV-negative subjects with TB but was only 40% among HIV-infected subjects [19] . In another evaluation, this assay correctly identified only 9 (11%) of 85 patients with TB who were also infected with HIV [20] . In Tanzania, the sensitivity of the MycoDot assay was only 16%, and the specificity was 84% [21] . Among HIV-infected subjects with paucibacillary disease, sensitivity of this assay was only 3% [21] . Results of these studies are consistent with those of the current study.
In the laboratory-based development phase, the ICS test showed promising performance when used to analyze banked serum specimens. However, in the field-testing phase, it lacked sufficient sensitivity as the sole test for TB. There was a significant reduction in test sensitivity when whole blood was used as the clinical sample. This result indicates that additional assay optimization is required to facilitate the use of whole blood in future clinical evaluations of the test.
The ELISA-based tests used in this study (Omega and Anda) were associated with a high rate of indeterminate results, which suggests that the cutoff values for the assays were suboptimal for use in the population in this study. It is possible that, with successive testing (which was not done in this study), the proportion of indeterminate test results may decrease. However, among those specimens that yielded an interpretable result, performance was also relatively poor. In general, it is thought that there is decreased mycobacterial antibody production in patients coinfected with M. tuberculosis and HIV that challenges the limits of detection of most ELISAs [22, 23] .
The most important limitation of this study is that M. tuberculosis culture is not a perfect gold standard for diagnosing TB, even when performed in conjunction with blood cultures. In addition, all eligible patients did not consent to participation, which may have resulted in an underestimation of the prevalence of HIV infection in this population, because lack of consent was most often the result of reluctance to undergo HIV testing. We did not test all available serodiagnostic assays and, therefore, cannot conclude that there is no test or combination of tests that could be useful in the development of a clinical algorithm for increasing the accuracy of diagnosing TB.
In conclusion, the serodiagnostic assays evaluated in this study are not sufficiently sensitive and specific for routine application in the diagnosis of TB in Botswana or similar regions where HIV infection is highly prevalent. Therefore, these assays fail the first performance criterion of the FDA for the ideal TB test (M. Goldberg, personal communication). Mycobacterial blood cultures should be considered as a viable adjunct to diagnosing TB in regions with a high volume of patients coinfected with HIV and TB and with the resources and technical capacity to permit their use.
